Pharmaceutical Group, which is comprised of 99 companies and approximately
31,000 people around the world. Otsuka and its consolidated subsidiaries
earned US $7.2 billion in consolidated annual revenues in fiscal 2006. For
additional information, please visit http://www.otsuka.com
1. Current Proposed PLR, October 19, 2007. Page 1. Supplied by Otsuka.
2. EVEREST, SALT-1, SALT-2
3. SHAPE Survey Results to the General Public, Annual Congress of the
European Society of Cardiology in Vienna, September 2003.
4. ACC News Release, "American College of Cardiology / American Heart
Association guidelines: New heart failure guidelines stress early diagnosis and treatment," August 16, 2005. Accessed at
m on March 1, 2007.
5. American Heart Association. Heart Disease and Stroke Statistics:
2005Update. Dallas, Tex: American Heart Association; 2005. as cited in
Gheorghiade M, et al. Circulation. 2005;112:3958-3968.
6. Schrier RW, Gheorghiade M, Gross P, et al. Results from the SALT 1 and
2 Trials. Multicenter, Randomized, Placebo-Controlled Trials in
Patients with Euvolemic and Hypervolemic Hyponatremia. Being Presented
at American Heart Association's Scientific Sessions in November 2006.
7. Adrogue HJ, Madias NE. Hyponatremia. NEJM. 2000; 342 (21):1581-1589.
8. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin V2 Receptor
Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of
Hyponatremia. AmJCardiol 2006;97:1064-1067.
Page: 1 2 3 Related biology technology :1
|SOURCE Otsuka Pharmaceutical Development & Commercialization,Inc.
Copyright©2007 PR Newswire.
All rights reserved
. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera2
. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product3
. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates4
. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications5
. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals6
. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development7
. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia8
. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA9
. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)10
. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications11
. Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications